Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (112,662,027)	$ (37,127,303)	$ (53,478,812)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development	72,523,293
Depreciation and amortization	4,403	12,829	28,834
Stockbased compensation	16,981,266	7,813,743	4,983,023
Amortization of right of use lease asset	182,042	258,848	200,776
Foreign currency (gain) loss	(281,534)	(317,402)	890,252
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	2,190,086	(109,338)	(472,402)
Accounts payable	(858,513)	(2,730,587)	2,326,767
Accrued expenses and other liabilities	(2,903,450)	(5,218,241)	3,928,684
Lease liability	(186,702)	(268,728)	(209,794)
Net cash used in operating activities	(25,011,136)	(37,686,179)	(41,802,672)
Cash flows from investing activities:
Purchases of property and equipment			(25,709)
Net cash used in investing activities			(25,709)
Cash flows from financing activities:
Proceeds from the exercise of stock options		208,367	150,949
Proceeds from at-the-market sales of common stock, net	682,973	1,538,645
Net cash provided by financing activities	682,973	1,747,012	150,949
Decrease in cash and cash equivalents	(24,328,163)	(35,939,167)	(41,677,432)
Effect of exchange rate changes on cash	38,758	(2,467)	606,249
Cash and cash equivalents-beginning of year	53,076,052	89,017,686	130,088,869
Cash and cash equivalents-end of period	28,786,647	53,076,052	$ 89,017,686
Non-cash investing and financing activities:
Operating lease liabilities arising from obtaining right-of-use assets	123,786	$ 124,043
Issuance of convertible preferred stock and common stock in connection with acquisition	$ 70,107,167